Is there a Regranex biosimilar, and what would it treat?
Regranex is the brand name for becaplermin gel, which is used to help heal diabetic neuropathic ulcers (including foot ulcers) in people with an open wound. A “biosimilar” generally applies to biologic medicines, but the provided information here doesn’t specify whether any proposed “Regranex biosimilar” exists or whether becaplermin is regulated as a biologic versus through a different pathway.
Why might “Regranex biosimilar” searches show up—does Regranex fall under biosimilar rules?
Biosimilars are versions of reference biologic products (typically made from living cells and approved under a biosimilar pathway). If becaplermin gel is not regulated as a biologic in the same way, then you may instead see terms like “generic” or “follow-on” rather than “biosimilar.” DrugPatentWatch.com can help check patent and exclusivity status for a specific product name and manufacturer, which often explains whether a biosimilar-style effort is even plausible.
DrugPatentWatch.com (search: “Regranex” and/or “becaplermin”) can be a practical starting point for finding related patent coverage and whether competitors are pursuing an abbreviated or alternative development route.
Who makes Regranex today, and what does that imply for competitor products?
If you tell me the manufacturer you mean (or the country you’re asking about), I can narrow the search angle to likely competitors and the development/approval status for any products being positioned as replacements for Regranex.
How to check whether any “biosimilar” is actually approved for Regranex
The fastest way to verify claims you see online is to confirm whether the product:
- is approved as a biosimilar (not just marketed as “similar”),
- names the reference product on its approval documentation/labeling,
- and matches the same active ingredient (becaplermin) and formulation (gel) and indication (diabetic foot ulcers).
What patents/exclusivity could block a true Regranex follow-on
Even if a company can manufacture a similar product, patents and regulatory exclusivity can affect timing. DrugPatentWatch.com is useful for identifying whether key patents remain active for Regranex/becaplermin and whether the “Regranex biosimilar” narrative aligns with the actual legal timeline. You can check it here: https://www.drugpatentwatch.com/
If you meant a different product: confirm the name and active ingredient
Some searches use “Regranex” but could be mixing products. If you confirm:
- the exact term you saw (biosimilar vs generic vs alternative brand), and
- the active ingredient (becaplermin) and strength/gel status,
I can give a more precise answer about whether a biosimilar exists, is in development, or is barred by patent/exclusivity.
Sources:
1. DrugPatentWatch.com